Investor Presentaiton

SELECT TRIALS-ORFORGLIPRON Lilly Primary Completion Completion Study Indication* Title Phase Patients Primary Outcome* ** NCT05971940 Type 2 Diabetes A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise (ACHIEVE-1) 3 520 Change from Baseline in Hemoglobin A1c (HbA1c) Jan 2025 Jan 2025 NCT05803421 Type 2 Diabetes A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4) 3 2620 Time to First Occurrence of Any Major Adverse Cardiovascular Event (MACE-4) [Myocardial Infarction (MI),| Stroke, Hospitalization for Unstable Angina, or Cardiovascular (CV) Death] Jan 2025 Sep 2025 NCT05872620 Obesity A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2) 3 1500 Mean Percent Change from Baseline in Body Weight Jun 2025 Jun 2025 NCT05931380 Obesity A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease (ATTAIN-J) 3 236 Mean Percent Change in Body Weight Jun 2025 Jul 2025 NCT05869903 Obesity A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1) 3 3000 Mean Percent Change from Baseline in Body Weight Sep 2025 Sep 2027 * Molecule may have multiple indications ** Trial may have additional primary and other secondary outcomes Not for promotional use Source: clinicaltrials.gov, August 2, 2023 2023 Q2 EARNINGS 43

View entire presentation